Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies (2023)
- Authors:
- Autor USP: ULRICH, ALEXANDER HENNING - IQ
- Unidade: IQ
- DOI: 10.1016/j.drup.2023.100988
- Subjects: NEOPLASIAS; PURINAS; PROLIFERAÇÃO CELULAR
- Agências de fomento:
- Financiamento NKPs
- Financiamento NSFC
- Financiamento FAPESP
- Financiamento CNPq
- Financiamento AIRC
- Financiamento Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine
- Financiamento Sichuan Science and Technology Program
- Financiamento West China Hospital, Sichuan University
- Financiamento Guangdong Basic and Applied Basic Research Foundation
- Language: Inglês
- Imprenta:
- Source:
- Título: Drug Resistance Updates
- ISSN: 1368-7646
- Volume/Número/Paginação/Ano: v. 70, p. 1-13 art. 100988, 2023
- Este artigo possui versão em acesso aberto
- URL de acesso aberto
- Versão do Documento: Versão publicada (Published version)
-
Status: Artigo aberto em periódico híbrido (Hybrid Open Access) -
ABNT
JIA, Wenhui et al. Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies. Drug Resistance Updates, v. 70, p. 1-13 art. 100988, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.drup.2023.100988. Acesso em: 15 mar. 2026. -
APA
Jia, W., Huang, Z., Zhou, L., Liou, Y. -C., Virgilio, F. D., Ulrich, H., et al. (2023). Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies. Drug Resistance Updates, 70, 1-13 art. 100988. doi:10.1016/j.drup.2023.100988 -
NLM
Jia W, Huang Z, Zhou L, Liou Y-C, Virgilio FD, Ulrich H, Peter I, Zhang W, Huang C, Tang Y. Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies [Internet]. Drug Resistance Updates. 2023 ; 70 1-13 art. 100988.[citado 2026 mar. 15 ] Available from: https://doi.org/10.1016/j.drup.2023.100988 -
Vancouver
Jia W, Huang Z, Zhou L, Liou Y-C, Virgilio FD, Ulrich H, Peter I, Zhang W, Huang C, Tang Y. Purinergic signalling in cancer therapeutic resistance: From mechanisms to targeting strategies [Internet]. Drug Resistance Updates. 2023 ; 70 1-13 art. 100988.[citado 2026 mar. 15 ] Available from: https://doi.org/10.1016/j.drup.2023.100988 - Aluminum-induced alterations of purinergic signalling in embryonic neural progenitor cells
- Nitric oxide in the differentiation of neural stem cells and its interrelationship with purinergic system
- Spontaneous calcium oscilation are modulated by P2 purinergic receptors and control expression of neurogenesis related transcription factors (Oral communication)
- RNAi-based strategy to study the role of P2X7 receptor in the temporal lobe epilepsy
- Extracellular nucleotides and purinergic signaling as novel underappreciated pro-metastatic chemotactic factors for human lung cancer cells
- Purinergic signaling during Porphyromonas gingivalis infection
- Purinergic signaling in differentation and neural phenotype determination
- Novel roles of highly specific natural inhibitors of the angiotensin-converting enzyme
- Both P2X7-KO and CD73-KO mice display normal hematopoiesis in non-stress mediated steady state conditions
- Cell cycle regulation during neurogenesis in the embryonic and adult brain
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
3155870.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
